Here we review the role of AXL as a key protein mediating resistance to targeted BCR-ABL inhibition in CML and in resistance to chemotherapy and FLT3 inhibition in AML. The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.